Outlook Therapeutics Reports the US FDA Approval of Lytenava for Wet AMD 

Shots: 

• The US FDA has approved Outlook’s Lytenava (Bevacizumab-vikg) for wet AMD   

• Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 MAb targeting VEGF 

• Additionally, the approval is expected to provide LYTENAVA with 12 years of Reference Product Exclusivity under the BPCIA 

Ref:  Outlook Therapeutics |  Image: Outlook Therapeutics |  Press Release

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com